Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (153)	7/25/2006 12:31:31 PM
From: dr.praveen	Respond to of 3027

"Main disappointment is they didn't disclose the mystery generic" We'll save it for another rainy day:-)

To: rkrw who wrote (153)	7/31/2006 9:20:28 AM
From: dr.praveen	Read Replies (1) \| Respond to of 3027

Momenta Pharmaceuticals Files Investigational New Drug Application for Novel Anticoagulant for Acute Coronary Syndromes Monday July 31, 7:50 am ET Novel Compound Designed Using Momenta's Proprietary Technology CAMBRIDGE, Mass., July 31 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA - News), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that it has submitted an electronic Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a Phase I human clinical study of M118, the Company's lead novel development candidate. M118 is an anticoagulant designed specifically to treat acute coronary syndromes (ACS). Momenta developed M118 using its proprietary technology for the detailed analysis and design of complex sugar therapeutics. By isolating, characterizing and engineering the key sugar structures within heparin that contribute to anticoagulation, Momenta designed a proprietary compound that it believes could provide baseline anticoagulant therapy to treat ACS patients who require a coronary intervention, as well as those ACS patients who are medically managed, or do not require intervention in order to treat their coronary attack. M118 is designed to be a reversible and monitorable anticoagulant that has a pharmacokinetic profile similar to a low molecular weight heparin. Thus, M118 is designed to be a therapeutic option that can be used across a variety of ACS treatment paths. "M118 has the potential to be a significant future advancement in the treatment and management of ACS," said Alan Crane, CEO of Momenta. "We are very encouraged by our preclinical studies which show that M118 could be a potent agent that provides consistent, flexible and reversible anticoagulant therapy. We look forward to continuing to advance M118 into Phase I clinical trials in the coming months." "M118 illustrates the potential of our technology, particularly our ability to leverage analytics and engineering to create novel drug candidates," continued Mr. Crane. "The filing of the M118 IND also demonstrates our technology's capability to generate a large number of product opportunities as we add and advance both complex generic and novel products to our growing pipeline." Background on M118 M118 directly leverages Momenta's technology for characterizing complex mixtures, correlating specific chemical structures to biological activity, and applying these structure-function relationships to design therapies with improved clinical properties. This "rational" engineering process has resulted in a product design that we believe combines in one molecule, the best attributes of existing anticoagulants. A key unmet need in ACS is the lack of a flexible anticoagulant agent that can be used regardless of whether a patient requires coronary intervention or is treated medically with pharmacological agents. We believe M118 can directly overcome this challenge as it combines the advantageous properties of unfractionated heparin, a preferred agent in ACS because of its ability to be reversed and monitored, with the convenience and predictable pharmacokinetic properties of low molecular weight heparins. Based on preclinical studies, M118 has been shown to be at least as effective in inhibiting clot formation as unfractionated heparin without causing increased bleeding complications. Moreover, preclinical studies found that M118's anticoagulant activity was reversible by protamine sulfate, unlike currently marketed low molecular weight heparins or direct thrombin inhibitors. Finally, the preclinical studies also demonstrated that the level of anticoagulation provided by M118 can be readily monitored using standard point-of-care coagulation assays. Background on Acute Coronary Syndromes ACS is characteristically used to describe patients experiencing an acute myocardial infarction, or heart attack, as well as patients who present at hospitals with unstable angina, a transient blockage of a coronary artery. According to the National Hospital Discharge Survey, each year, there are more than 1.9 million occurrences of either unstable angina or myocardial infarction requiring medical treatment across the U.S. As part of the treatment of ACS, anticoagulant agents are routinely administered to prevent the accumulation and formation of blood clots which can lead to serious, life-threatening complications. About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. In accordance with its collaboration with Sandoz, the generics business of Novartis AG, an ANDA was submitted to the FDA for M-Enoxaparin in August 2005. Momenta has multiple technology-enabled generic products in its pipeline. Momenta's first novel drug candidate is M118. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA. To receive additional information about Momenta, please visit the website at momentapharma.com, which does not form a part of this press release.